Table 1 Comparison of clinicopathological characteristics between GC with MHSES and LSES.

Age (years)^a

62.5 (47.0–77.8)

61.0 (46.0–76.0)

63.0 (53.5–79.0)

0.575^b

  < 65

16 (53.3%)

8 (53.3%)

8 (53.3%)

1^c

  ≥ 65

14 (46.7%)

7 (46.7%)

7 (46.7%)

Sex

0.272^c

 Women

13 (43.3%)

8 (53.3%)

5 (33.3%)

 Men

17 (56.7%)

7 (46.7%)

10 (66.7%)

Albumin (g/dL)^a

3.4 (3.0–4.1)

4.1 (3.9–4.3)

3.0 (2.5–3.3)

 < 0.001^b

Hemoglobin (g/dL)^a

10.3 (6.6–11.2)

11.2 (10.6–12.5)

7.8 (5.7–9.6)

 < 0.001^b

Tumor size (mm)^a

35.0 (15.0–57.5)

40.0 (25.5–76.5)

30.0 (12.5–45.0)

0.114^b

Lauren classification

1^c

 Mixed

3 (10.0%)

2 (13.3%)

1 (6.7%)

 Intestinal

17 (56.7%)

8 (53.3%)

9 (60.0%)

 Diffuse

10 (33.3%)

5 (33.3%)

5 (33.3%)

Borrmann classification

0.651^c

 I–II

6 (20.0%)

4 (26.7%)

2 (13.3%)

 III–IV

24 (80.0%)

11 (73.3%)

13 (86.7%)

Location of tumor

0.044^c

 Body-Antrum

2 (6.7%)

2 (13.3%)

0 (0.0%)

 Antrum

13 (43.3%)

4 (26.7%)

9 (60.0%)

 Body

11 (36.7%)

5 (33.3%)

6 (40.0%)

 Fundus

4 (13.3%)

4 (26.7%)

0 (0.0%)

Clinical stage

0.597^c

 I–II

4 (13.3%)

3 (20.0%)

1 (6.7%)

 III–IV

26 (86.7%)

12 (80.0%)

14 (93.3%)

Microsatellite status

1^c

 MS-Stable

23 (88.5%)

12 (92.3%)

11 (85.0%)

 MSI-High

3 (11.5%)

1 (7.7%)

2 (15.0%)

 No determined

4

2

2

Tumor mutational burden (Muts/Mb)^a

5.0 (3.0–8.0)

3.0 (3.0–5.0)

6.0 (3.0–8.0)

0.377^b

TMB by groups

0.371^c

 High (≥ 20 Muts/mb)

3 (11.5%)

1 (7.7%)

2 (15.4%)

 Medium (6–19 Muts/mb)

7 (26.9%)

2 (15.4%)

5 (38.5%)

 Low (1–5 Muts/mb)

16 (61,5%)

10 (76.9%)

6 (46.1%)

 No determined

4

2

2